Upstream Bio, Inc. (UPB)
Automate Your Wheel Strategy on UPB
With Tiblio's Option Bot, you can configure your own wheel strategy including UPB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol UPB
- Rev/Share 0.0506
- Book/Share 7.6016
- PB 2.7586
- Debt/Equity 0.0038
- CurrentRatio 38.2718
- ROIC -0.2958
- MktCap 1130480684.0
- FreeCF/Share -2.1301
- PFCF -9.8701
- PE -10.7933
- Debt/Assets 0.0037
- DivYield 0
- ROE -0.359
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | UPB | Truist | -- | Buy | -- | $47 | Oct. 14, 2025 |
News
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data support the potential of verekitug's unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respiratory diseases – WALTHAM, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented structural and mechanistic data showing verekitug's potent pharmacodynamic …
Read More
Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, on Sunday, June 15, 2025.
Read More
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 – – First patient in Phase 2 clinical trial of verekitug in patients with chronic obstructive pulmonary disease to be dosed in mid-2025 – WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe …
Read More
Upstream Bio to Present at Upcoming March Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Upstream Bio's CEO, will present at the following upcoming March investor conferences: TD Cowen 45th Annual Health Care Conference, Boston MA Tuesday, March 4, 2025, 11:50 a.m.
Read More
About Upstream Bio, Inc. (UPB)
- IPO Date 2024-10-11
- Website https://upstreambio.com
- Industry Biotechnology
- CEO E. Rand Sutherland M.P.H., MPH
- Employees 52